Your Dose of Cannabis Education

Your Dose of Cannabis Education

Only have a minute but want to Learn something every day? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.

Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education

Wake up every morning and get your dose of unbiased evidence-based cannabis education!

Bennabis Health

We’re making medical cannabis
more affordable and
understandable!

Use code BENNABISHEALTH to save 20% on any CME Course.

Visit the Bennabis Health website.

2024-03-28
Some cancer patients use medical marijuana to treat various cancer-associated ailments. What are some of the ailments ameliorated by medical marijuana?
According to one study involving 96 cancer patients receiving supportive cancer care, the data support the safety and effectiveness of medical marijuana as a complementary option for improving pain control, appetite and quality of life for cancer patients. The top three adverse events of this study included drowsiness, low energy and nausea, and were reported in 28% of patients, with 9% having to stop using the medical marijuana. (Note: other studies indicate that chemotherapy-induced nausea and vomiting is ameliorated by medical marijuana.)
Vigano A, Aprikian S, Kasvis P. et al. Safety and effectiveness of medical cannabis as a complementary option for supportive cancer care: Results from the Cannabis Pilot Project. Journal of Clinical Oncology 2020 38:15_suppl, 12106-12106
2024-03-27
Side effects of short-term cannabinoid-based therapy may differ from person to person, and the same person may experience different side effects at different times. What factors influence the probability and the severity of adverse events?
Many factors influence the likelihood and the severity of adverse events, including the type of cannabinoid preparation; the mode of administration; the dose administered; the patient’s expectations, the patient's prior experience with cannabinoid-based therapies, and the age of the patient. Drug–drug interactions may also lead to adverse events.
Vulfsons, S., Minerbi, A and Sahar T, .Cannabis and Pain Treatment—A Review of the Clinical Utility and a Practical Approach in Light of Uncertainty Rambam Maimonides Med J | www.rmmj.org.il Jan 2020  Vol 11  Issue 1
2024-03-26
What is Sativex®?
Sativex® is a buccal (oral) spray containing Δ-9-THC and CBD (2.7 mg Δ-9-THC and 2.5 mg CBD per spray) and it is indicated for spasticity and neuropathic pain in multiple sclerosis, and as adjunctive analgesia for moderate to severe cancer pain. While Sativex® is approved in several European countries, Canada, and other countries, it has not been approved for medical use in the U.S.
Brown JD and Winterstein A. Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) UseJ. Clin. Med. 2019, 8(7), 989; https://doi.org/10.3390/jcm8070989 Review
2024-03-25
According to the results of a survey of breast cancer patients’ use of cannabinoid products before, during, and after cancer treatment, 42% of survey participants had used medical cannabinoid products to relieve symptoms. What symptoms were treated with the cannabinoid products?
Members of the Breastcancer.org and Healthline communities were asked to participate in a survey. Among the 832 respondents who completed screening, 725 met the eligibility criteria, and 612 (84%) completed the survey. According to the results, the symptoms for which cannabinoids were used included insomnia (70%), pain (59%), anxiety (57%), stress (51%), and nausea/vomiting (46%). The results also indicated that cannabinoids were used prior to cancer treatment in 24%, during treatment in 79%, and after treatment in 54%. Of subjects reporting cannabis use during treatment: 86% used it during chemotherapy, 71% during HER2 therapy, 65% during hormonal therapy, 49% during breast radiation, and 47% during radiation for metastatic sites. Post-surgical use was reported in 51% after mastectomy alone, 40% after lumpectomy, and 38% after mastectomy/reconstruction.
Weiss MC,, Hibbs J, McHugh T et al. A survey of breast cancer patients’ use of cannabis before, during, and after treatment. Journal of Clinical Oncology 2020 38:15_suppl, e19210-e19210
2024-03-24
Are cannabinoids an effective analgesic agent in the chronic pain setting?
In contrast to the lack of efficacy in the acute pain setting, cannabinoids are effective analgesic agents in the chronic pain setting. According to 2 systematic reviews involving a total of 29 randomized controlled trials (RCTs), 22 of the 29 RCTs demonstrated that cannabinoids have a modest analgesic effect in the management of chronic pain. The following modes of administration/products were examined in the RCTs: smoked cannabis (6 trials), oromucosal and oral cannabis extract (11 trials), nabilone (8 trials), dronabinol (2 trials), THC-11 acid analogue (2 trials), and fatty acid amide hydrolase inhibitor (1 trial).
Vulfsons, S., Minerbi, A and Sahar T, .Cannabis and Pain Treatment—A Review of the Clinical Utility and a Practical Approach in Light of Uncertainty Rambam Maimonides Med J | www.rmmj.org.il Jan 2020  Vol 11  Issue 1

Learn something every day in your feed…

Follow @The_Answer_Page

New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.